RWD(Real World Data) 시장 : 데이터 소스별, 용도별, 최종 사용자별, 지역별 예측(-2036년)
Real-World Data Market by Source, Application, End User, and Geography - Global Forecast to 2036
상품코드:1947419
리서치사:Meticulous Research
발행일:On Demand Report
페이지 정보:영문 212 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 RWD(Real World Data) 시장은 2026년 14억 5,000만 달러로 추정되고, 예측 기간(2026-2036년)에 CAGR 6.4%로 성장할 전망이며, 2036년까지 약 27억 달러에 이를 것으로 전망되고 있습니다. 본 보고서에서는 5개 주요 지역에서 세계의 RWD(Real World Data) 시장에 대해 현재 시장 동향, 시장 규모, 최근 동향, 2036년까지의 예측에 중점을 두고 상세한 분석을 제공합니다. 광범위한 2차 조사와 1차 조사 및 시장 시나리오의 상세한 분석을 통해 주요 업계의 촉진요인, 억제요인, 기회, 과제의 영향 분석을 실시했습니다. RWD(Real World Data) 시장의 성장을 견인하는 주요 요인으로는 세계의 의료 업계에서 가치 기반 의료로의 전환, 의약품 개발 기간의 단축 요구 증가, 의사 결정에 있어서의 리얼 월드 에비던스의 규제 당국에 의한 수용 확대, 의료 분야의 급속한 디지털화 등이 있습니다. 또한 AI와 고급 분석 기술의 통합, 분산형 임상시험 확대, 환자 중심의 데이터 수집, 맞춤형 의료의 이니셔티브가 RWD(Real World Data) 시장에서 사업을 전개하는 기업들에게 큰 성장 기회를 창출할 것으로 예측됩니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
데이터 소스별 시장 분석
용도별 시장 분석
최종 사용자별 시장 분석
지역별 시장 분석
경쟁 분석
제4장 시장 인사이트
시장 성장 촉진요인
가치 기반 의료로의 전환 및 의약품 개발 비용 상승
리얼 월드 에비던스의 규제 당국에 의한 수용 확대
의료 분야에서 빅 데이터 채용 확대
시장 성장 억제요인
데이터 프라이버시 및 보안에 대한 우려
데이터 표준화 및 상호 운용성의 부족
시장 기회
맞춤형 의료 및 미충족 치료 영역
인공지능(AI) 및 고급 분석 기술의 통합
시장 과제
데이터 품질 및 무결성 문제
복잡한 규제 상황의 대응
시장 동향
분산형 및 환자 중심의 데이터 수집의 확대
환자 생성 건강 데이터(PGHD)의 중요성 증가
Porter's Five Forces 분석
제5장 세계의 RWD(Real World Data) 시장 : 데이터 소스별
전자 의료 기록(EMR/EHR) 및 임상 데이터
청구 및 과금 데이터
약국 데이터
제품 및 질환 레지스트리 데이터
유전체 데이터
환자 생성 데이터 및 웨어러블 데이터
기타 정보원
제6장 세계의 RWD(Real World Data) 시장 : 용도별
의약품 개발 및 승인
시장 액세스, 상환 및 지불자 결정
시판 후 조사
의료기기 개발 및 승인
임상 및 규제상의 의사 결정
제7장 세계의 RWD(Real World Data) 시장 : 최종 사용자별
제약, 생명공학 및 의료기기 기업
의료보험자
의료 제공업체
기타 최종 사용자
제8장 세계의 RWD(Real World Data) 시장 : 지역별
북미
미국
캐나다
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
아시아태평양
중국
일본
인도
기타 아시아태평양
라틴아메리카
중동 및 아프리카
제9장 경쟁 구도
주요 성장 전략
경쟁 대시보드
주요 기업별 시장 점유율 및 랭킹
제10장 기업 프로파일
IQVIA Inc.
Merative
Optum Inc.
ICON plc
Syneos Health
Aetion, Inc.
Flatiron Health, Inc.
Verana Health
Oracle Corporation
SAS Institute Inc.
Parexel International Corporation
Elevance Health, Inc.
Others
제11장 부록
AJY
영문 목차
영문목차
Real-World Data (RWD) Market by Source (EHR, Claims, Clinical Trials, Pharmacy, Patient-Reported), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Region - Global Forecast to 2036
According to the research report titled, 'Real-World Data (RWD) Market by Source (EHR, Claims, Clinical Trials, Pharmacy, Patient-Reported), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Region - Global Forecast to 2036,' the global real-world data market is expected to reach approximately USD 2.7 billion by 2036 from USD 1.45 billion in 2026, at a CAGR of 6.4% during the forecast period (2026-2036). The report provides an in-depth analysis of the global real-world data market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The major factors driving the growth of the real-world data market include the global healthcare industry's shift toward value-based care, rising need to accelerate drug development timelines, increasing regulatory acceptance of real-world evidence for decision-making, and rapid digitalization of healthcare. Additionally, AI and advanced analytics integration, expansion of decentralized clinical trials, patient-centric data collection, and personalized medicine initiatives are expected to create significant growth opportunities for players operating in the real-world data market.
Key Players
The key players operating in the global real-world data market are IQVIA Inc. (U.S.), Merative (U.S.), Optum Inc. (U.S.), Aetion, Inc. (U.S.), Flatiron Health, Inc. (U.S.), Verana Health (U.S.), ICON plc (Ireland), Syneos Health (U.S.), and various other regional and emerging analytics companies, data providers, and clinical research organizations, among others.
Market Segmentation
The real-world data market is segmented by source (EHR/EMR/Clinical Data, Claims, Clinical Trials, Pharmacy, Patient-Reported/Wearable Data), application (drug development & approvals, market access & reimbursement, post-market surveillance), end user (pharmaceutical & biotechnology companies, payers, providers), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Based on Source
By source, the EMR/EHR/Clinical Data segment accounts for around 45-50% of the overall real-world data market in 2026, reflecting the widespread adoption of electronic health records in healthcare systems globally. EHRs contain detailed clinical information including diagnoses, medications, lab results, and physician notes. However, the Patient-Generated/Wearable Data segment is expected to grow at the fastest CAGR during the forecast period, driven by the proliferation of consumer wearables and digital health apps capturing continuous, real-time data on patient physiology and behavior. Claims data, clinical trials data, and pharmacy records represent important complementary sources.
Based on Application
By application, the Drug Development & Approvals segment holds the largest share of the overall real-world data market in 2026, accounting for around 35-40% of total revenue. Pharmaceutical and biotechnology companies leverage RWD across the entire drug lifecycle, from trial design to regulatory submissions. The Market Access & Reimbursement/Payer Decisions segment is also a major consumer of RWD, as payers require robust evidence of a drug's real-world effectiveness and value. Post-market surveillance represents a growing application area for ongoing safety monitoring.
Based on End User
By end user, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to witness the fastest CAGR during the forecast period, as these organizations increasingly adopt RWD to optimize drug development and market access strategies. Payers (insurance companies, healthcare systems) use RWD for coverage decisions and reimbursement negotiations. Providers (hospitals, clinics) leverage RWD to optimize treatment pathways and improve patient outcomes.
Geographic Analysis
An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global real-world data market with the largest market share, primarily attributed to advanced healthcare IT infrastructure, high adoption of EHRs, and a favorable regulatory environment. The 21st Century Cures Act and FDA guidance have created a clear framework for RWE use in regulatory submissions. Europe's growth is driven by initiatives like the European Health Data Space and EMA's DARWIN EU network. Asia-Pacific is poised to be the fastest-growing region during the forecast period, fueled by massive government investments in healthcare digitalization in countries like China and Singapore, a rapidly expanding pharmaceutical market, and growing clinical trial landscape.
Key Questions Answered in the Report-
What is the current revenue generated by the real-world data market globally?
At what rate is the global real-world data market demand projected to grow for the next 7-10 years?
What are the historical market sizes and growth rates of the global real-world data market?
What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
Which segments in terms of source, application, and end user are expected to create major traction for the service providers in this market?
What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global real-world data market?
Who are the major players in the global real-world data market? What are their specific service offerings in this market?
What are the recent strategic developments in the global real-world data market? What are the impacts of these strategic developments on the market?
Scope of the Report:
Real-World Data (RWD) Market Assessment -- by Source
EMR/EHR/Clinical Data
Claims Data
Clinical Trials Data
Pharmacy Data
Patient-Reported/Wearable Data
Real-World Data (RWD) Market Assessment -- by Application
Drug Development & Approvals
Market Access & Reimbursement/Payer Decisions
Post-Market Surveillance
Other Applications
Real-World Data (RWD) Market Assessment -- by End User
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Payers (Insurance Companies, Healthcare Systems)
Providers (Hospitals, Clinics)
Other End Users
Real-World Data (RWD) Market Assessment -- by Geography
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
South Korea
Singapore
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa
TABLE OF CONTENTS
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.2. Bottom-Up Approach
2.3.3. Top-Down Approach
2.3.4. Growth Forecast
2.4. Assumptions for the Study
3. Executive Summary
3.1. Overview
3.2. Market Analysis, by Source
3.3. Market Analysis, by Application
3.4. Market Analysis, by End User
3.5. Market Analysis, by Geography
3.6. Competitive Analysis
4. Market Insights
4.1. Introduction
4.2. Global Real-World Data Market: Impact Analysis of Market Drivers (2026-2036)
4.2.1. Shift Toward Value-Based Care and Rising Drug Development Costs
4.2.2. Increasing Regulatory Acceptance of Real-World Evidence
4.2.3. Growing Adoption of Big Data in Healthcare
4.3. Global Real-World Data Market: Impact Analysis of Market Restraints (2026-2036)
4.3.1. Data Privacy and Security Concerns
4.3.2. Lack of Data Standardization and Interoperability
4.4. Global Real-World Data Market: Impact Analysis of Market Opportunities (2026-2036)
4.4.1. Personalized Medicine and Underserved Therapeutic Areas
4.4.2. Integration of AI and Advanced Analytics
4.5. Global Real-World Data Market: Impact Analysis of Market Challenges (2026-2036)
4.5.1. Data Quality and Completeness Issues
4.5.2. Navigating Complex Regulatory Landscapes
4.6. Global Real-World Data Market: Impact Analysis of Market Trends (2026-2036)
4.6.1. Expansion of Decentralized and Patient-Centric Data Collection
4.6.2. Growing Importance of Patient-Generated Health Data (PGHD)
